Effect of PPARγ2 Polymorphism and NSAIDs on Acute Alcohol-induced Changes in Serum Estrogens Among Post-menopausal Women (EPPNASE)
Primary Purpose
Breast Cancer
Status
Completed
Phase
Early Phase 1
Locations
Denmark
Study Type
Interventional
Intervention
Ibuprofen Tab 400 MG
Placebo tab
Sponsored by

About this trial
This is an interventional basic science trial for Breast Cancer focused on measuring PPAR-gamma, estrogens, NSAIDS, polymorphism, metabolomics
Eligibility Criteria
Inclusion Criteria:
- postmenopausal (last menses at least 1 year earlier);
- having a weekly alcohol use of less than 14 drinks
- having a BMI of 18-35;
Exclusion Criteria:
- a history of alcohol abuse
- alcohol abstaining
- history of hysterectomy before last menses with preservation of both ovaries (unless a medical confirmation for the postmenopausal status exists or the participant is 60 years or older);
- major health problems, such as ulcers, heart diseases, diabetes or cancer
- previous or current use of HRT
- taking prescription medications that could interfere with the study (i.e. daily use of NSAIDs and/or medication that interact with PPARγ e.g. cholesterol lowering medicine);
- being allergic to alcohol and/or Ibuprofen
- smoking
Sites / Locations
- Department of Nutrition, Exercise and Sports, University of Copenhagen
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Sequence 1
Sequence 2
Arm Description
Ibuprofen Tab 400MG Placebo Tab
Placebo tab Ibuprofen Tab 400MG
Outcomes
Primary Outcome Measures
Serum estrone sulphate (pmol/l)
Plasma estrone sulfate concentration after acute ethanol intake by Ibuprofen intake and/or PPARG genotype
Secondary Outcome Measures
Serum estrone (pmol/l)
Plasma estrone decrease after acute ethanol intake by ibuprofen intake and/or PPARG genotype
Serum SHBG (nmol/l)
Plasma SHBG concentration after acute ethanol ingestion by ibuprofen intake and/or PPARG genotype
Serum ethanol (g/l)
Plasma ethanol concentration after acute ethanol ingestion
Serum metabolomics (relative metabolite intensity)
The plasma metabolome profile by time after alcohol intake
Urine metabolomics (relative metabolite intensity)
The urine metabolome profile by time after alcohol intake
Full Information
NCT ID
NCT02463383
First Posted
May 17, 2015
Last Updated
December 11, 2017
Sponsor
Professor Lars Ove Dragsted
Collaborators
Technical University of Denmark
1. Study Identification
Unique Protocol Identification Number
NCT02463383
Brief Title
Effect of PPARγ2 Polymorphism and NSAIDs on Acute Alcohol-induced Changes in Serum Estrogens Among Post-menopausal Women
Acronym
EPPNASE
Official Title
Alcohol-related Breast Cancer in Postmenopausal Women - Effect of PPARG2pro12ala Polymorphism on Female Sex-hormone Levels and Interaction With Alcohol Consumption and NSAID Usage
Study Type
Interventional
2. Study Status
Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Professor Lars Ove Dragsted
Collaborators
Technical University of Denmark
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Postmenopausal women, stratified by a peroxisome proliferator-activated receptor gamma-2 (PPARG) polymorphism, were given the following treatments in a random order with a 5w wash-out period: a 400mg ibuprofen tablet or a placebo tablet; both treatments were followed after 30min by a single acute dose of 0.4g alcohol per kg bw. Serum estrogen levels were measured before and at three timepoints after alcohol intake. It is hypothesized that the acute decrease in estrogen sulphate and other markers of estrogens after alcohol intake is modulated by ibuprofen and by PPARG genotype.
Detailed Description
In a pilot human intervention trial we aimed to determine the effect of the PPARG Pro12Ala polymorphism and the PPARγ stimulator, Ibuprofen, on sex-hormone levels following alcohol intake in postmenopausal women. Seven women with PPARG Pro12Ala and 18 PPARG wildtype women were included.The study was performed as a randomised, double-blinded, placebo controlled 2x24 h crossover study. The volunteers were randomised to 1 of 2 groups who got the two treatments in different orders. Treatment 1 was a placebo tablet with water followed after 30min by an alcoholic drink providing 0,4g alcohol per kilogram bw and treatment 2 was an Ibuprofen tablet (400mg) with water followed by the same alcoholic drink. The two treatments were separated by a 5-7 weeks washout period. Alcohol was supplied as 7.7% ethanol in a lime-flavoured drink and was consumed over 15 min. EDTA-plasma was collected 40min before and 30, 60 and 90 min after ethanol intake as well as after 24 hours. Ibuprofen (400mg) was provided together with 100mL water 30min before the ethanol. Urine was collected throughout the 24 hour interval. Serum estrone, estrone sulphate, serum estrogen-binding globulin (SHBG), and ethanol were determined. It is hypothesized that the acute decrease in estrogen sulphate and other markers of estrogens after alcohol intake is modulated by ibuprofen and by PPARG genotype.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
PPAR-gamma, estrogens, NSAIDS, polymorphism, metabolomics
7. Study Design
Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Crossover Assignment
Model Description
Participants are randomized to an ibuprofen or placebo pill in the first period and are then provided with placebo or ibuprofen pills, respectively, in the second period in a crossover fashion. Alcohol (0.4g/kg bw) is provided as a challenge 30min after the pill has been swallowed.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sequence 1
Arm Type
Experimental
Arm Description
Ibuprofen Tab 400MG
Placebo Tab
Arm Title
Sequence 2
Arm Type
Experimental
Arm Description
Placebo tab
Ibuprofen Tab 400MG
Intervention Type
Drug
Intervention Name(s)
Ibuprofen Tab 400 MG
Other Intervention Name(s)
(RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid
Intervention Description
400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
Intervention Type
Drug
Intervention Name(s)
Placebo tab
Other Intervention Name(s)
placebo tablet
Intervention Description
A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
Primary Outcome Measure Information:
Title
Serum estrone sulphate (pmol/l)
Description
Plasma estrone sulfate concentration after acute ethanol intake by Ibuprofen intake and/or PPARG genotype
Time Frame
from 40 min before to 90 min after alcohol consumption
Secondary Outcome Measure Information:
Title
Serum estrone (pmol/l)
Description
Plasma estrone decrease after acute ethanol intake by ibuprofen intake and/or PPARG genotype
Time Frame
from 40 min before to 90 min after alcohol consumption
Title
Serum SHBG (nmol/l)
Description
Plasma SHBG concentration after acute ethanol ingestion by ibuprofen intake and/or PPARG genotype
Time Frame
from 40 min before to 90 min after alcohol consumption
Title
Serum ethanol (g/l)
Description
Plasma ethanol concentration after acute ethanol ingestion
Time Frame
from 40 min before to 90 min after alcohol consumption
Title
Serum metabolomics (relative metabolite intensity)
Description
The plasma metabolome profile by time after alcohol intake
Time Frame
from 40 min before to 24h after alcohol intake
Title
Urine metabolomics (relative metabolite intensity)
Description
The urine metabolome profile by time after alcohol intake
Time Frame
from 40 min before to 24h after alcohol intake
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
postmenopausal (last menses at least 1 year earlier);
having a weekly alcohol use of less than 14 drinks
having a BMI of 18-35;
Exclusion Criteria:
a history of alcohol abuse
alcohol abstaining
history of hysterectomy before last menses with preservation of both ovaries (unless a medical confirmation for the postmenopausal status exists or the participant is 60 years or older);
major health problems, such as ulcers, heart diseases, diabetes or cancer
previous or current use of HRT
taking prescription medications that could interfere with the study (i.e. daily use of NSAIDs and/or medication that interact with PPARγ e.g. cholesterol lowering medicine);
being allergic to alcohol and/or Ibuprofen
smoking
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lars O Dragsted, PhD
Organizational Affiliation
University of Copenhagen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Nutrition, Exercise and Sports, University of Copenhagen
City
Frederiksberg
ZIP/Postal Code
1958
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
27102200
Citation
Kopp TI, Jensen DM, Ravn-Haren G, Cohen A, Sommer HM, Dragsted LO, Tjonneland A, Hougaard DM, Vogel U. Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial. BMC Cancer. 2016 Apr 21;16:283. doi: 10.1186/s12885-016-2317-y.
Results Reference
derived
Learn more about this trial
Effect of PPARγ2 Polymorphism and NSAIDs on Acute Alcohol-induced Changes in Serum Estrogens Among Post-menopausal Women
We'll reach out to this number within 24 hrs